Fintel reports that on November 4, 2025, Citizens maintained coverage of Vertex (NasdaqGM:VERX) with a Market Outperform ...

Fintel reports that on November 4, 2025, Stifel maintained coverage of Vertex (NasdaqGM:VERX) with a Hold recommendation.

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Vertex Pharmaceuticals (VRTX) swung to profitability as the company left behind five years of annual earnings declines ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows ...

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.